SCHEMBL3899461

SCHEMBL3899461

O=C(O)c1ccccc1NS(=O)(=O)C1=CC=CN2SNC=C12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.44
KMT2A Q03164 9/20 0.44
KDM4E B2RXH2 4/20 0.44
POLB P06746 2/20 0.44
ALDH1A1 P00352 8/20 0.41
HSD17B10 Q99714 5/20 0.41
HPGD P15428 3/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
WDR5 P61964 1/20 0.37
PMM2 O15305 1/20 0.37
HCRTR1 O43613 1/20 0.37
G6PD P11413 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3746024 0.85 ACLY (0.41) MEN1KMT2AKDM4EALDH1A1
SCHEMBL3741031 0.85 ACLY (0.39) MEN1KMT2AWDR5
SCHEMBL3745363 0.85 ACLY (0.49)
SCHEMBL7820189 0.85 METAP2 (0.47) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL3747308 0.85 ACLY (0.47) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL1882959 0.85 ACLY (0.37) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL3911355 0.84 MAPT (0.44) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL3905746 0.83 ACLY (0.49) MEN1KMT2AGAAERAP1
SCHEMBL3901306 0.82 ALDH1A1 (0.43) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL3902675 0.81 KDM4E (0.42) MEN1KMT2AKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1675837-A2 BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-05 EP disclosed
WO-2005012275-A2 BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-10 WO disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR MEN1 2768/4885KMT2A 3053/4885KDM4E 4124/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 MEN1 2441/4885KMT2A 3281/4885KDM4E 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.